Morgan Lewis

Life Sciences Protecting the Complete Life Cycle

For More Information

Read the Brochure

Life Sciences and Healthcare

Life Sciences Deskbook

New Resource

New Resource: Health Industry Transparency Compliance Resource Center

Emerging Business Tools

visit the Entrepreneur Resource Headquarters

Practice Highlights

Honors

PLCCross-border Quarterly 2011/12 Life Sciences Legal Market Review

  • Life Sciences Regulatory Super League - Ranked 10th of law firms worldwide

PLCCross-border Life Sciences Handbook 2011/12

  • U.S.:
    • Commercial and Partnering - Highly Recommended
    • Competition/Antitrust - Highly Recommended
    • Corporate - Recommended
    • Government Enforcement and Investigations - Highly Recommended
    • Regulatory - Recommended
    • Regulatory (Medical Devices) - Recommended
  • England: Regulatory - Recommended
  • Japan: Corporate and Commercial - Recommended

Chambers Global 2011: Global Life Sciences - Recommended - Band 3

Chambers USA 2011: National for Life Sciences - Band 3; Washington, D.C. for healthcare/ pharmaceutical/ medical products regulatory - Band 3

UK Legal 500 2010: London: Pharmaceuticals and Biotechnology

Best Lawyers in America 2011: Biotechnology and Healthcare Law Named

BioPharm Insight 2011
(based on last 12 months)

  • Ranked 1st in Legal Advisers on Asia-Pacific Licensing Agreements - Based on Volume
  • Ranked 4th in Legal Advisers on European Licensing Agreements - Based on Volume
  • Ranked 5th in Global League Table of Legal Advisers on Licensing Agreements - Based on Volume
  • Ranked 5th in Global League Table of Legal Advisers on Licensing Agreements - Based on Value
(based on Q1 2011)
  • Ranked 4th in Global League Table of Legal Advisers on Licensing Agreements - Based on Volume
  • Ranked 5th in Global League Table of Legal Advisers on Licensing Agreements - Based on Value
U.S. News & World Report/Best Lawyers 2010: Ranked Tier 1 National Practice - Biotechnology

Clients

16 of the top 20 pharmaceutical companies

7 of the top 20 biotechnology companies

9 of the top 20 medical device companies

Related Events

02/27/12-02/29/12 ACI’s 16th Advanced Forum on Structuring, Negotiating, and Managing Life Sciences Collaborative Agreements and Acquisitions New York
Fahd Riaz, panelist, "Preparing Your IP for M&A or Product License: What Savvy Buyers Look For"
02/29/12-03/02/12 2012 IMS Managed Markets Services/DataNiche Conference Las Vegas, NV
Donna Lee Yesner, speaker
03/22/12-03/24/12 ABA Section of Business Law Spring Meeting 2012 Las Vegas, NV
Arianne Callender, panelist, "New and Evolving Threats from the Responsible Corporate Officers Doctrine"
View all events

Related News

01/04/12 Former VP and Deputy GC of Cephalon Joins Morgan Lewis
Morgan Lewis today announces that Steven A. Reed has joined the firm as a partner in its Litigation Practice, resident in Philadelphia.
01/20/11 Morgan Lewis Advises Perrigo on $540 Million Acquisition of Paddock Assets
Morgan Lewis advised Perrigo Company, a global healthcare products supplier, on its acquisition of nearly all of the assets of Paddock Laboratories, Inc. for $540 million in cash.
10/29/10 Morgan Lewis Advises Safeguard Scientifics on $587 Million Sale of Clarient to GE Healthcare
In a transaction valued at $587 million, Clarient, Inc. has agreed to be acquired by GE Healthcare.
View all news

Related Publications

02/06/12 CMS Proposes Major Changes to AMP Rule
The Proposed Rule provides provisions that will significantly impact pharmaceutical manufacturers' rebate liability, price reporting calculations, and possibly their operations.
02/03/12 Class Action Arbitration Waiver Rejected by Federal Appellate Court
Second Circuit sidesteps Concepcion and holds that the ability to enforce federal statutory rights mandates that a plaintiff be allowed to pursue a class action in court notwithstanding the parties' agreement to mandatory arbitration.
View all publications

With more than 200 lawyers, scientists and other technical specialists who focus on the life sciences industry, we have one of the most comprehensive practices of any U.S. law firm. Unlike other law firms, we understand the scientific, business, and regulatory issues that our clients face and have expanded our practice to include more than 60 professionals with advanced life sciences degrees.

Our clients include many of the largest and most successful pharmaceutical companies in the world, as well as a long list of biotechnology companies, medical device manufacturers, nutritional companies, healthcare providers, renowned research and scientific institutions, and life sciences-focused investment banks and venture capital firms. As diverse as they are, these companies share a common need for comprehensive, integrated legal services that address all of the business issues and opportunities facing the industry.

Having expressly developed our capabilities to cover seamlessly the complete life sciences product lifecycle, we offer an unsurpassed mix of services that are critical to this industry. Our Life Sciences practice focuses on all important areas, from transactions and litigation to regulatory approvals and compliance and protection of intellectual property, as well as key supporting capabilities, including FDA and healthcare, patents and patent litigation, labor and employment law, Morgan Lewis Resources workplace training and immigration, and antitrust. As a full-service firm with offices in the financial and regulatory centers of central importance to the industry in the U.S., Europe and Asia, we are uniquely situated to provide counseling for the full range of business activities.